Article
10 Oct 2025
TrumpRx: What Pharmacies And Plan Sponsors Need To Know
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
09 Oct 2025
Rolling With The Changes: Navigating Marijuana Rescheduling
Article
28 Aug 2025
Rapid Rundown: Latest On Marijuana Rescheduling From An FDA Perspective
Article
27 Aug 2025
Delta-8 Dilemma: FDA Issues Another Warning Letter
Article
04 Aug 2025
Clear The Air: FDA Cracks Down On Illegal Vapes Entering The U.S.
Article
18 Jul 2025
No More Baby Steps: FDA Call To Action To Enhance Recall Communications For Infant Formula, Baby Foods, And Foods Intended For Children
Article
26 Jun 2025
Color Us Intrigued: Staying Ahead Of FDA's Regulatory Changes For Colors
Article
25 Jun 2025
Paving A New Path: FDA Rolls Out New Incentive For Drug Developers
Article
29 May 2025
State Importation Revamped: FDA Announces Enhancements To State Importation For Eligible Prescription Drugs
Article
28 May 2025
Patent Predicament: FTC Revives Challenges To Over 200 Patent Listings
Article
22 May 2025
Formula For Change: FDA Open The Door For Input On Nutrient Requirements For Infant Formula
Article
19 May 2025
Tianeptine: The War Rages On
Article
21 Mar 2025
Navigating Medicaid Drug Rebate Program (MDRP) Compliance: A Guide For Pharmaceutical Manufacturers
Article
04 Feb 2025
FDA Reopens Door For Flavored Cigars And Menthol Cigarettes
Article
31 Jan 2025
FDA Grants Marketing Order For ZYN Nicotine Pouches
Article
20 Jan 2025
4 Potential FDA Drug Approvals To Watch In 2025
Article
17 Dec 2024
FDA Issues 115 Warning Letters To Retailers Selling Unauthorized E-Cigarettes
Article
25 Oct 2024
FDA Sets Date For The Digital Health Advisory Committee Meeting To Discuss Generative Artificial Intelligence-Enabled Devices
Article
23 Oct 2024
FDA Releases Final Guidance On The Review Of Drug Master Files In Advance Of Certain ANDA Submissions Under GDUFA
Article
18 Oct 2024
FDA Announces Public Workshop On Nonprescription Analgesic/Antipyretic Drug Development In Children 2 To Less Than 12 Years Of Age